Clinical Trial Update: MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MK-2206 in combination with anastrozole and/or fulvestrant in postmenopausal women with metastatic breast cancer; study status is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Invasive Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Fulvestrant (fulvestrant)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Positive, Invasive Breast Carcinoma | Phase 1 | Status: COMPLETED